Abstract
We report our experience with isolated hepatic perfusion (IHP) with tumor necrosis factor (TNF) and melphalan in an experimental pig study and of a phase I study in humans. IHP was performed with inflow catheters in the hepatic artery and portal vein and an outflow catheter in the caval vein. An extracorporeal venovenous bypass was used. IHP consisted of a 60-min perfusion with hyperthermia (> 41 °C). For the pig protocol rhTNFα 50 μg/kg alone (n = 5) or rhTNFα 50 μg/kg plus melphalan 1 mg/kg (n = 3) were added. In two control pigs no drugs were added. In the phase I study, patients received melphalan 1 mg/kg with 0.4 mg rhTNFα (n = 8) or 0.8 mg rhTNFα (n = 1). After the perfusion the liver was washed with Macrodex before vascular continuity was restored. All pigs but one survived the procedure. Systemic leakage was less than 0.02%. Transient, mild liver toxicity was seen in all pigs, including controls, as demonstrated by liver enzyme assays and histology. There was no significant hemodynamic, cardiopulmonary hemotological, or renal toxicity. In the phase I clinical study there was leakage in one patient (cumulative leakage 20%). There were three perioperative deaths (one possibly drug-related). All patients demonstrated significant hepatotoxicity. Survival ranged from 6 to 26 months (median 10.3 months). All patients demonstrated a tumor response (partial response 5/6, 1/6 stable disease) with a median duration of 18 weeks. In contrast to our pig program, many problems were encountered in the phase I study. By using both the hepatic artery and portal vein for IHP we encountered more toxicity than expected based on data from the pig program, resulting in fatal coagulative disturbances in one patient who received the second rhTNFα dose. Furthermore, local control after one IHP with TNFα and melphalan is only temporary.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kusthai G (1991) Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51: 5602–5607
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175: 323–329
Aigner KR (1988) Isolated liver perfusion: 5-year-results. Reg Cancer Treat 1: 11–20
Archer SG, Gray BN (1989) Vascularization of small liver metastases. Br J Surg 76: 545–548
Bördel Rinkes IHM, De Vries MR, Jonker AM, Swaak TJG, Hack CE, Nooijen PTGA, Wiggers T, Eggermont AMM (1997) Isolated hepatic perfusion in the pig with TNFα with and without melphalan. Br J Cancer (in press)
Busam KJ, Bauer TM, Bauer J, Gerok W, Decker B (1990) Interleukin-6 release by rat liver macrophages. J Hepatol 11: 367–373
Carswell EA, Old JJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 72: 3666–3670
De Brauw LM, Van de Velde CJH, Tjaden LR, De Bruijn EA, Bell AVRJ, Hermans J, Zwaveling A (1988) In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue. J Surg Res 44: 137–145
De Takats PG, Kerr DJ, Poole CJ, Warren HW, McArdle CS (1994) Hepatic arterial chemotherapy for metastatic colorectal carcinoma (review). Br J Cancer 69: 372–378
Eggermont AMM, Schraffordt Koops H, Klausner JM. ( 1996 a) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224: 756–765
De Vries MR, Borel Rinkes IHM, Buurman WA, Wiggers T, Van de Velde CJH, Eggermont AMM (1995 a) Soluble TNFa receptor induction by isolated hepatic perfusion with TNFa and melphalan. Eur J Surg Res 27(S1):108
De Vries MR, Borel Rinkes IHM, Hack CE, Wiggers T, Van de Velde CJH, Kuppen PJK, Eggermont AMM (1995 b) Isolated hepatic perfusion with TNFa and melphalan: local and systemic effects on secondary cytokine release, coagulation and fibrinolysis. Eur J Surg Res 27(S1):109
Eggermont AMM, Schraffordt Koops H, Lienard D, Kroon BBR, Van Geel AN, Hoekstra HJ, Lejeune FJ (1996 b) Isolated limb perfusion with high-dose tumor necrosis factor a in combination with interferon y and melphalan for nonresectable extremity soft tissue sar-comas: a multicenter trial. J Clin Oncol 14: 2653–2665
Feinberg B, Kurzrock R, Talpaz M et al (1988) A phase I trial of intravenously administered recombinant tumor necrosis factor in patients with advanced cancer. J Clin Oncol 6: 1328–1334
Genari L (1992) Liver metastases: a many-sided therapeutical problem. Hepatogastroenterology 39: 5–9
Hack CE, Hart M, Strack van Schijndel A et al (1992) Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immunol 60: 2835–2842
Helle M, Boeije L, De Groot ER, De Vos A, Aarden LA (1991) Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 138: 42–56
Kahky MP, Daniel CO, Cruz AB, Gaskill HV (1990) Portal infusion of tumor necrosis factor increases mortality in rats. J Surg Res 49: 138–145
Ku Y, Fukumoto T, Iwasaki T et al (1995) Clinical pilot study with high-dose intraarterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma. Surgery 117: 510–519
Leeuwenberg JFM, Jeunhomme TMAA, Buurman WA (1994) Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 152: 4036–4043
Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolated perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 50–62
Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL, Eggermont AMM (1996) Synergistic antitumor effect of recombinant human tumor necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551–555
Marinelli A, Dijkstra FR, Van Dierendonck JH, Kuppen PJK, Cornelisse CJ, Van de Velde CJH (1991) Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumor of rat colorectal cancer. Br J Cancer 64: 74–78
Que FG, Nagorney DM (1994) Resection of ‘recurrent’ colorectal metastases to the liver. Br J Surg 81: 255–258
Renard N, Lienard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (TNFa) Int J Cancer 57: 656–663
Skibba JL, Almagro UA, Condon RE, Petroff RJ Jr (1983) A technique for isolated perfusion of the canine liver with survival. J Surg Res 34: 123–132
Spriggs DR, Sherman ML, Micjie H. (1988) Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacological study. J Natl Cancer Inst 80: 1039–1044
Strohmeyer T, Haugeberg G, Lierse W (1986) Vaskularisation von Lebermetastasen: eine korrosionsanatomische Studie. Acta Anat (Basel) 126: 172–176
Swaak AJG, Lienard D, Schrafforgt Koops H, Lejeune FJ, Eggermont AMM (1993) Effects of recombinant tumour necrosis factor (rTNFa) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose Rtnfα administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 23: 812–818
Vreugdenhil G, Lowenberg B, Van Eijk HG, Swaak AJ (1992) Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 22: 488–493
Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM (1984) The natural history of hepatic metastases from colorectal origin. A comparison with resective treatment. Ann Surg 199: 502–508
Weber J, Yang JC, Topalian SL et al (1993) Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 11: 499–506
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
de Vries, M.R. et al. (1998). Isolated Hepatic Perfusion with Tumor Necrosis Factor α and Melphalan: Experimental Studies in Pigs and Phase I Data from Humans. In: Oldhafer, K.J., Lang, H., Pichlmayr, R. (eds) Isolated Liver Perfusion for Hepatic Tumors. Recent Results in Cancer Research, vol 147. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80460-1_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-80460-1_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-80462-5
Online ISBN: 978-3-642-80460-1
eBook Packages: Springer Book Archive